|Videos|March 19, 2015

When to Image: Earlier?

Episodes in this series

Now Playing

EP. 1 When to Image: Earlier?

EP. 2 Looking Forward: Immunotherapy and Genomics

EP. 3 MAINSAIL: Lessons Learned

EP. 4 Abiraterone: Approval and Use

EP. 5 Sequencing: Important Question With Many Answers

EP. 6 A Review of Bone-Targeted Therapies

EP. 7 Changes in NCCN Guideline: Affecting Second-Line

EP. 8 Sipuleucel-T: Evidence-based Use

EP. 9 Considerations in Treatment Selection

EP. 10 Changes in NCCN Guideline: Affecting First-Line

EP. 11 Prostate Cancer: Which Guidelines

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

September 28th, 2026

Calculating the Real Cost of False Positive Findings in Cancer Screening

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

Perioperative Durvalumab Plus EV in MIBC | Image Credit: © Adin - stock.adobe.com

September 25th, 2026

FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC

FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.

Bladder Cancer | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

September 18th, 2026

CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC

The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.